Identification

Name
Probenecid
Accession Number
DB01032  (APRD00167)
Type
Small Molecule
Groups
Approved
Description

The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. [PubChem]

Structure
Thumb
Synonyms
  • 4-((Dipropylamino)sulfonyl)benzoic acid
  • 4-(Di-N-propylsulfamoyl)benzoesaeure
  • 4-(N,N-Dipropylsulfamoyl)benzoesaeure
  • P-(Dipropylsulfamoyl)benzoic acid
  • Probenecid acid
  • Probenecida
  • Probenecide
  • Probenecidum
External IDs
HC 5006 / NSC-18786
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Benemid Tab 500mgTablet500 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1952-12-312000-08-03Canada
BenurylTablet500 mgOralValeant Canada Lp Valeant Canada S.E.C.1974-12-312016-07-08Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ProbenecidTablet, film coated500 mg/1OralAphena Pharma Solutions Tennessee, Inc.1976-07-29Not applicableUs
ProbenecidTablet, film coated500 mg/1OralWatson Pharmaceuticals1983-07-01Not applicableUs
ProbenecidTablet, film coated500 mg/1OralCarilion Materials Management1976-01-13Not applicableUs
ProbenecidTablet, film coated500 mg/1OralMylan Pharmaceuticals1976-01-13Not applicableUs
ProbenecidTablet, film coated500 mg/1OralPhysicians Total Care, Inc.1995-03-28Not applicableUs00591 5347 01 nlmimage10 260e1360
ProbenecidTablet, film coated500 mg/1OralMarlex Pharmaceuticals Inc1976-07-29Not applicableUs
ProbenecidTablet, film coated500 mg/1OralAphena Pharma Solutions Tennessee, Inc.1976-01-13Not applicableUs
ProbenecidTablet, film coated500 mg/1OralLannett Company, Inc.1976-07-29Not applicableUs
ProbenecidTablet, film coated500 mg/1OralAmerincan Health Packaging2015-03-31Not applicableUs
ProbenecidTablet, film coated500 mg/1OralHHS/Program Support Center/Supply Service Center1983-07-01Not applicableUs
International/Other Brands
Benecid / Benemid / Probalan / Probecid / Proben
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Pro Biosan KitProbenecid (500 mg) + Ampicillin (500 mg)Capsule; TabletOralIcn Pharmaceuticals1979-12-311998-08-13Canada
Probenecid and ColchicineProbenecid (500 mg/1) + Colchicine (.5 mg/1)TabletOralAv Kare, Inc.2012-05-082016-02-05Us
Probenecid and ColchicineProbenecid (500 mg/1) + Colchicine (.5 mg/1)TabletOralRising Pharmaceuticals2008-05-13Not applicableUs
Probenecid and ColchicineProbenecid (500 mg/1) + Colchicine (.5 mg/1)TabletOralWatson Pharmaceuticals1982-10-01Not applicableUs00591 5325 01 nlmimage10 240e1210
Probenecid and ColchicineProbenecid (500 mg/1) + Colchicine (.5 mg/1)TabletOralIngenus Pharmaceuticals Nj, Llc2008-05-13Not applicableUs
Categories
UNII
PO572Z7917
CAS number
57-66-9
Weight
Average: 285.359
Monoisotopic: 285.103478791
Chemical Formula
C13H19NO4S
InChI Key
DBABZHXKTCFAPX-UHFFFAOYSA-N
InChI
InChI=1S/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16)
IUPAC Name
4-(dipropylsulfamoyl)benzoic acid
SMILES
CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O

Pharmacology

Indication

For the reduction of serum uric acid concentrations in chronic gouty arthritis and tophaceous gout in patients with frequent disabling gout attacks. Has also been effectively used to promote uric acid excretion in hyperuricemia secondary to the administration of thiazide and related diuretics.

Structured Indications
Pharmacodynamics

Probenecid is a uricosuric and renal tubular blocking agent and is used in combination with colchicine to treat chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout. It inhibits the reabsorption of urate at the proximal convoluted tubule, thus increasing the urinary excretion of uric acid and decreasing serum urate levels. Effective uricosuria reduces the miscible urate pool, retards urate deposition, and promotes resorption of urate deposits. At the proximal and distal tubles, probenecid competitively inhibits the secretion of many weak organic acids including penicillins, most cephalosporins, and some other β-lactam antibiotics. This results in an increase in the plasma concentrations of acidic drugs eliminated principally by renal secretion, but only a slight increase if the drug is eliminated mainly by filtration. Thus, the drug can be used for therapeutic advantages to increase concentrations of certain β-lactam antibiotics in the treatment of gonorrhea, neurosyphilis, or pelvic inflammatory disease (PID).

Mechanism of action

Probenecid inhibits the tubular reabsorption of urate, thus increasing the urinary excretion of uric acid and decreasing serum urate levels. Probenecid may also reduce plasma binding of urate and inhibit renal secretion of uric acid at subtherapeutic concentrations. The mechanism by which probenecid inhibits renal tubular transport is not known, but the drug may inhibit transport enzymes that require a source of high energy phosphate bonds and/or nonspecifically interfere with substrate access to protein receptor sites on the kidney tubules.

TargetActionsOrganism
ASolute carrier family 22 member 6
inhibitor
Human
ASolute carrier family 22 member 11
inhibitor
Human
ASolute carrier family 22 member 8
inhibitor
Human
UPannexin-1
antagonist
Human
UTaste receptor type 2 member 16Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

75-95%

Metabolism
Not Available
Route of elimination

Excreted principally in the urine as monoacyl glucuronide and unchanged drug. Alkalinization of urine increases renal probenecid excretion.

Half life

6-12 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Glucose-6-phosphate 1-dehydrogenaseVilleurbanneNot Available1000_1002delACCADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTorunNot Available1006A->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSunderlandNot Available105_107delCATADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIwatsukiNot Available1081G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSerresNot Available1082C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTondelaNot Available1084_1101delCTGAACGAGCGCAAGGCCADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLoma LindaNot Available1089C->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAachenNot Available1089C->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTenriNot Available1096A->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMontpellierNot Available1132G>AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCalvo MackennaNot Available1138A->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRileyNot Available1139T->CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOlomoucNot Available1141T->CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTomahNot Available1153T->CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLynwoodNot Available1154G->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMadridNot Available1155C->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIowa, Walter Reed, SpringfieldNot Available1156A->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBeverly Hills, Genova, Iwate, Niigata, YamaguchiNot Available1160G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHartfordNot Available1162A->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePrahaNot Available1166A->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKrakowNot Available1175T>CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWisconsinNot Available1177C->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNashville, Anaheim, PorticiNot Available1178G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAlhambraNot Available1180G->CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBariNot Available1187C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePuerto LimonNot Available1192G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCovao do LoboNot Available1205C>AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseClinicNot Available1215G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUtrechtNot Available1225C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSuwalkiNot Available1226C->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRiversideNot Available1228G->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseJapan, ShinagawaNot Available1229G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKawasakiNot Available1229G->CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMunichNot Available1231A->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseGeorgiaNot Available1284C->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSumareNot Available1292T->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTelti/KobeNot Available1318C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSantiago de Cuba, MoriokaNot Available1339G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHarimaNot Available1358T->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFiguera da FozNot Available1366G->CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmiensNot Available1367A>TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBangkok NoiNot Available1376G->T, 1502T->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFukayaNot Available1462G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCampinasNot Available1463G->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBuenos AiresNot Available1465C>TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseArakawaNot Available1466C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBrightonNot Available1488_1490delGAAADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKozukataNot Available159G->CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmsterdamNot Available180_182delTCTADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNo nameNot Available202G->A, 376A->G, 1264C>GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSwanseaNot Available224T->CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUrayasuNot Available281_283delAGAADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseVancouverNot Available317C->G544C->T592C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMt SinaiNot Available376A->G, 1159C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePlymouthNot Available488G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseVolendamNot Available514C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseShinshuNot Available527A->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChikugoNot Available535A->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTsukuiNot Available561_563delCTCADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePedoplis-CkaroNot Available573C>GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSantiagoNot Available593G->CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMinnesota, Marion, Gastonia, LeJeuneNot Available637G->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCincinnatiNot Available637G->T, 1037A->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHarilaouNot Available648T->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNorth DallasNot Available683_685delACAADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAsahikawaNot Available695G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseDurhamNot Available713A->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseStonybrookNot Available724_729delGGCACTADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWayneNot Available769C->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAveiroNot Available806G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCleveland CorumNot Available820G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLilleNot Available821A>TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBangkokNot Available825G>CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSugaoNot Available826C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLa JollaNot Available832T->CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWexhamNot Available833C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePiotrkowNot Available851T>CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWest VirginiaNot Available910G->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOmiyaNot Available921G->CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNaraNot Available953_976delCCACCAAAGGGTACCTGGAC GACCADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseManhattanNot Available962G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRehevotNot Available964T->CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHoniaraNot Available99A->G / 1360C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTokyo, FukushimaNot Available1246G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChathamNot Available1003G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFushanNot Available1004C->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePartenopeNot Available1052G->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIerapetraNot Available1057C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAnadiaNot Available1193A->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAbenoNot Available1220A->CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSurabayaNot Available1291G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePawneeNot Available1316G->CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseS. AntiocoNot Available1342A->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCassanoNot Available1347G->CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHermoupolisNot Available1347G->C / 1360C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUnion,Maewo, Chinese-2, KaloNot Available1360C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAndalusNot Available1361G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCosenzaNot Available1376G->CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCanton, Taiwan- Hakka, Gifu-like, Agrigento-likeNot Available1376G->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFloresNot Available1387C->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKaiping, Anant, Dhon, Sapporo-like, WoseraNot Available1388G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKamogawaNot Available169C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCostanzoNot Available179T>CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmazoniaNot Available185C->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSongklanagarindNot Available196T->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHechiNot Available202G->A / 871G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNamouruNot Available208T->CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBao LocNot Available352T>CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCrispimNot Available375G->T, 379G->T383T->C384C>TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAcrokorinthosNot Available376A->G / 463C->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSanta MariaNot Available376A->G / 542A->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAnanindeuaNot Available376A->G / 871G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseVanua LavaNot Available383T->CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseValladolidNot Available406C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBelemNot Available409C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLiuzhouNot Available442G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseShenzenNot Available473G>AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTaipei “Chinese- 3”Not Available493A->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseToledoNot Available496C>TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNaoneNot Available497G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNankangNot Available517T->CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMiaoliNot Available519C->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMediterranean, Dallas, Panama‚ Sassari, Cagliari, BirminghamNot Available563C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCoimbra ShundeNot Available592C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNilgiriNot Available593G>AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRadlowoNot Available679C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRoubaixNot Available811G>CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHaikouNot Available835A->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChinese-1Not Available835A->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMizushimaNot Available848A>GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOsakaNot Available853C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseViangchan, JammuNot Available871G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSeoulNot Available916G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLudhianaNot Available929G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFarroupilhaNot Available977C->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChinese-5Not Available1024C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRignanoNot Available130G>AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOrissaNot Available131C->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseG6PDNiceNot Available1380G>CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKamiube, KeelungNot Available1387C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNeapolisNot Available1400C->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAuresNot Available143T->CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSplitNot Available1442C->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKambosNot Available148C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePalestrinaNot Available170G>AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMetapontoNot Available172G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMusashinoNot Available185C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAsahiNot Available202G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (202), Ferrara INot Available202G->A / 376A->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMurcia OristanoNot Available209A->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUbe KonanNot Available241C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLagosantoNot Available242G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseGuangzhouNot Available274C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHammersmithNot Available323T->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSinnaiNot Available34G->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (680)Not Available376A->G / 680G->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (968), Betica,Selma, GuantanamoNot Available376A->G / 968T->CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSalerno PyrgosNot Available383T>GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseQuing YanNot Available392G->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLagesNot Available40G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIleshaNot Available466G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMahidolNot Available487G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMalagaNot Available542A->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSibariNot Available634A->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMexico CityNot Available680G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNanningNot Available703C->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSeattle, Lodi, Modena, Ferrara II, Athens-likeNot Available844G->CADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBajo MaumereNot Available844G->TADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMontalbanoNot Available854G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKalyan-Kerala, Jamnaga, RohiniNot Available949G->AADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseGaoheNot Available95A->GADR InferredIncreased risk of aplastic anemia, leukopenia and hemolytic anemia.Details

Interactions

Drug Interactions
DrugInteractionDrug group
AceclofenacThe serum concentration of Aceclofenac can be increased when it is combined with Probenecid.Approved, Investigational
AcemetacinThe serum concentration of Acemetacin can be increased when it is combined with Probenecid.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Probenecid.Approved
AcetohexamideThe protein binding of Acetohexamide can be decreased when combined with Probenecid.Investigational, Withdrawn
Acetylsalicylic acidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe serum concentration of Adapalene can be increased when it is combined with Probenecid.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Probenecid.Approved
AlclofenacThe serum concentration of Alclofenac can be increased when it is combined with Probenecid.Approved, Withdrawn
AlminoprofenThe serum concentration of Alminoprofen can be increased when it is combined with Probenecid.Experimental
AloxiprinThe therapeutic efficacy of Probenecid can be decreased when used in combination with Aloxiprin.Experimental
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be increased when it is combined with Probenecid.Experimental, Investigational
AmdinocillinThe serum concentration of Amdinocillin can be increased when it is combined with Probenecid.Investigational, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Probenecid.Approved
Aminosalicylic AcidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Aminosalicylic Acid.Approved
AmoxicillinThe serum concentration of Amoxicillin can be increased when it is combined with Probenecid.Approved, Vet Approved
AmpicillinThe serum concentration of Ampicillin can be increased when it is combined with Probenecid.Approved, Vet Approved
AndrographolideThe serum concentration of Andrographolide can be increased when it is combined with Probenecid.Investigational
AnisodamineThe serum concentration of Anisodamine can be increased when it is combined with Probenecid.Investigational
AntipyrineThe serum concentration of Antipyrine can be increased when it is combined with Probenecid.Approved
ApocyninThe serum concentration of Apocynin can be increased when it is combined with Probenecid.Investigational
ApremilastThe serum concentration of Apremilast can be increased when it is combined with Probenecid.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Probenecid.Approved, Investigational
AspoxicillinThe serum concentration of Aspoxicillin can be increased when it is combined with Probenecid.Experimental
AvibactamThe serum concentration of Avibactam can be increased when it is combined with Probenecid.Approved
AzapropazoneThe serum concentration of Azapropazone can be increased when it is combined with Probenecid.Withdrawn
AzelastineThe serum concentration of Azelastine can be increased when it is combined with Probenecid.Approved
AzidocillinThe serum concentration of Azidocillin can be increased when it is combined with Probenecid.Approved
AzlocillinThe serum concentration of Azlocillin can be increased when it is combined with Probenecid.Approved
BacampicillinThe serum concentration of Bacampicillin can be increased when it is combined with Probenecid.Approved, Investigational
BalsalazideThe serum concentration of Balsalazide can be increased when it is combined with Probenecid.Approved, Investigational
BendazacThe serum concentration of Bendazac can be increased when it is combined with Probenecid.Experimental
BenorilateThe serum concentration of Benorilate can be increased when it is combined with Probenecid.Experimental
BenoxaprofenThe serum concentration of Benoxaprofen can be increased when it is combined with Probenecid.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Benzathine benzylpenicillin can be increased when it is combined with Probenecid.Approved, Vet Approved
Benzoic AcidThe serum concentration of Benzoic Acid can be increased when it is combined with Probenecid.Approved
BenzydamineThe serum concentration of Benzydamine can be increased when it is combined with Probenecid.Approved
BenzylpenicillinThe serum concentration of Benzylpenicillin can be increased when it is combined with Probenecid.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Benzylpenicilloyl Polylysine can be increased when it is combined with Probenecid.Approved
BevoniumThe serum concentration of Bevonium can be increased when it is combined with Probenecid.Experimental
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Probenecid.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Probenecid.Approved
BromfenacThe serum concentration of Bromfenac can be increased when it is combined with Probenecid.Approved
BucillamineThe serum concentration of Bucillamine can be increased when it is combined with Probenecid.Investigational
BufexamacThe serum concentration of Bufexamac can be increased when it is combined with Probenecid.Experimental
BumadizoneThe serum concentration of Bumadizone can be increased when it is combined with Probenecid.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Probenecid is combined with Bumetanide.Approved
Carbaspirin calciumThe therapeutic efficacy of Probenecid can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbenicillinThe serum concentration of Carbenicillin can be increased when it is combined with Probenecid.Approved, Investigational
Carbenicillin indanylThe serum concentration of Carbenicillin indanyl can be increased when it is combined with Probenecid.Approved, Investigational
CarbutamideThe protein binding of Carbutamide can be decreased when combined with Probenecid.Experimental
CarfecillinThe serum concentration of Carfecillin can be increased when it is combined with Probenecid.Experimental
CarprofenThe serum concentration of Carprofen can be increased when it is combined with Probenecid.Approved, Vet Approved, Withdrawn
CastanospermineThe serum concentration of Castanospermine can be increased when it is combined with Probenecid.Experimental
CefacetrileThe serum concentration of Cefacetrile can be increased when it is combined with Probenecid.Approved
CefaclorThe serum concentration of Cefaclor can be increased when it is combined with Probenecid.Approved
CefadroxilThe serum concentration of Cefadroxil can be increased when it is combined with Probenecid.Approved, Vet Approved, Withdrawn
CefalotinThe serum concentration of Cefalotin can be increased when it is combined with Probenecid.Approved, Vet Approved
CefamandoleThe serum concentration of Cefamandole can be increased when it is combined with Probenecid.Approved, Investigational
CefapirinThe serum concentration of Cefapirin can be increased when it is combined with Probenecid.Approved, Vet Approved
CefatrizineThe serum concentration of Cefatrizine can be increased when it is combined with Probenecid.Experimental
CefazedoneThe serum concentration of Cefazedone can be increased when it is combined with Probenecid.Experimental
CefazolinThe serum concentration of Cefazolin can be increased when it is combined with Probenecid.Approved
CefbuperazoneThe serum concentration of Cefbuperazone can be increased when it is combined with Probenecid.Experimental
CefetametThe serum concentration of Cefetamet can be increased when it is combined with Probenecid.Experimental
CefiximeThe serum concentration of Cefixime can be increased when it is combined with Probenecid.Approved
CefmenoximeThe serum concentration of Cefmenoxime can be increased when it is combined with Probenecid.Approved
CefmetazoleThe serum concentration of Cefmetazole can be increased when it is combined with Probenecid.Approved, Investigational
CefminoxThe serum concentration of Cefminox can be increased when it is combined with Probenecid.Approved
CefodizimeThe serum concentration of Cefodizime can be increased when it is combined with Probenecid.Experimental
CefonicidThe serum concentration of Cefonicid can be increased when it is combined with Probenecid.Approved, Investigational
CefoperazoneThe serum concentration of Cefoperazone can be increased when it is combined with Probenecid.Approved, Investigational
CeforanideThe serum concentration of Ceforanide can be increased when it is combined with Probenecid.Approved
CefotaximeThe serum concentration of Cefotaxime can be increased when it is combined with Probenecid.Approved
CefotetanThe serum concentration of Cefotetan can be increased when it is combined with Probenecid.Approved
CefotiamThe serum concentration of Cefotiam can be increased when it is combined with Probenecid.Approved, Investigational
CefoxitinThe serum concentration of Cefoxitin can be increased when it is combined with Probenecid.Approved
CefpodoximeThe serum concentration of Cefpodoxime can be increased when it is combined with Probenecid.Approved, Vet Approved
CefradineThe serum concentration of Cefradine can be increased when it is combined with Probenecid.Approved
CefroxadineThe serum concentration of Cefroxadine can be increased when it is combined with Probenecid.Withdrawn
CefsulodinThe serum concentration of Cefsulodin can be increased when it is combined with Probenecid.Experimental
CeftazidimeThe serum concentration of Ceftazidime can be increased when it is combined with Probenecid.Approved
CeftezoleThe serum concentration of Ceftezole can be increased when it is combined with Probenecid.Experimental
CeftizoximeThe serum concentration of Ceftizoxime can be increased when it is combined with Probenecid.Approved, Investigational
CeftobiproleThe serum concentration of Ceftobiprole can be increased when it is combined with Probenecid.Approved, Investigational
CeftriaxoneThe serum concentration of Ceftriaxone can be increased when it is combined with Probenecid.Approved
CefuroximeThe serum concentration of Cefuroxime can be increased when it is combined with Probenecid.Approved
CelecoxibThe serum concentration of Celecoxib can be increased when it is combined with Probenecid.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be increased when it is combined with Probenecid.Approved, Vet Approved
CephaloglycinThe serum concentration of Cephaloglycin can be increased when it is combined with Probenecid.Approved
CephaloridineThe serum concentration of Cephaloridine can be increased when it is combined with Probenecid.Approved, Withdrawn
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Probenecid.Approved, Vet Approved
ChlorpropamideThe protein binding of Chlorpropamide can be decreased when combined with Probenecid.Approved
Choline magnesium trisalicylateThe serum concentration of Choline magnesium trisalicylate can be increased when it is combined with Probenecid.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Probenecid.Approved
CinoxacinThe serum concentration of Cinoxacin can be increased when it is combined with Probenecid.Approved, Investigational, Withdrawn
ClonixinThe serum concentration of Clonixin can be increased when it is combined with Probenecid.Approved
CloxacillinThe serum concentration of Cloxacillin can be increased when it is combined with Probenecid.Approved, Vet Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Probenecid.Approved
CurcuminThe serum concentration of Curcumin can be increased when it is combined with Probenecid.Investigational
CyclacillinThe serum concentration of Cyclacillin can be increased when it is combined with Probenecid.Approved
D-LimoneneThe serum concentration of D-Limonene can be increased when it is combined with Probenecid.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Probenecid.Approved
DapsoneThe serum concentration of Dapsone can be increased when it is combined with Probenecid.Approved, Investigational
dersalazineThe therapeutic efficacy of Probenecid can be decreased when used in combination with dersalazine.Investigational
DexketoprofenThe serum concentration of Dexketoprofen can be increased when it is combined with Probenecid.Approved, Investigational
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Probenecid.Approved, Vet Approved
DicloxacillinThe serum concentration of Dicloxacillin can be increased when it is combined with Probenecid.Approved, Vet Approved
DifenpiramideThe serum concentration of Difenpiramide can be increased when it is combined with Probenecid.Experimental
DiflunisalThe therapeutic efficacy of Probenecid can be decreased when used in combination with Diflunisal.Approved
DoripenemThe serum concentration of Doripenem can be increased when it is combined with Probenecid.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Probenecid.Approved, Investigational
DroxicamThe serum concentration of Droxicam can be increased when it is combined with Probenecid.Approved
DuvelisibThe serum concentration of Duvelisib can be increased when it is combined with Probenecid.Investigational
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Probenecid.Approved
E-6201The serum concentration of E-6201 can be increased when it is combined with Probenecid.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Probenecid.Approved
EnoxacinThe serum concentration of Enoxacin can be increased when it is combined with Probenecid.Approved, Investigational
EpicillinThe serum concentration of Epicillin can be increased when it is combined with Probenecid.Experimental
EpirizoleThe serum concentration of Epirizole can be increased when it is combined with Probenecid.Approved
ErtapenemThe serum concentration of Ertapenem can be increased when it is combined with Probenecid.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Probenecid is combined with Etacrynic acid.Approved
EtanerceptThe serum concentration of Etanercept can be increased when it is combined with Probenecid.Approved, Investigational
EthenzamideThe serum concentration of Ethenzamide can be increased when it is combined with Probenecid.Experimental
EtodolacThe serum concentration of Etodolac can be increased when it is combined with Probenecid.Approved, Investigational, Vet Approved
EtofenamateThe serum concentration of Etofenamate can be increased when it is combined with Probenecid.Approved, Investigational
EtoricoxibThe serum concentration of Etoricoxib can be increased when it is combined with Probenecid.Approved, Investigational
Evening primrose oilThe serum concentration of Evening primrose oil can be increased when it is combined with Probenecid.Approved, Investigational
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Probenecid.Approved
exisulindThe serum concentration of exisulind can be increased when it is combined with Probenecid.Investigational
FelbinacThe serum concentration of Felbinac can be increased when it is combined with Probenecid.Experimental
FenbufenThe serum concentration of Fenbufen can be increased when it is combined with Probenecid.Approved
FenoprofenThe serum concentration of Fenoprofen can be increased when it is combined with Probenecid.Approved
FentiazacThe serum concentration of Fentiazac can be increased when it is combined with Probenecid.Experimental
FeprazoneThe serum concentration of Feprazone can be increased when it is combined with Probenecid.Experimental
Ferulic acidThe serum concentration of Ferulic acid can be increased when it is combined with Probenecid.Experimental
FleroxacinThe serum concentration of Fleroxacin can be increased when it is combined with Probenecid.Approved
FloctafenineThe serum concentration of Floctafenine can be increased when it is combined with Probenecid.Approved, Withdrawn
FlucloxacillinThe serum concentration of Flucloxacillin can be increased when it is combined with Probenecid.Approved, Investigational
FlumequineThe serum concentration of Flumequine can be increased when it is combined with Probenecid.Withdrawn
FlunixinThe serum concentration of Flunixin can be increased when it is combined with Probenecid.Vet Approved
FlunoxaprofenThe serum concentration of Flunoxaprofen can be increased when it is combined with Probenecid.Experimental
FlurbiprofenThe serum concentration of Flurbiprofen can be increased when it is combined with Probenecid.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Probenecid is combined with Furosemide.Approved, Vet Approved
GanciclovirThe serum concentration of Ganciclovir can be increased when it is combined with Probenecid.Approved, Investigational
GarenoxacinThe serum concentration of Garenoxacin can be increased when it is combined with Probenecid.Investigational
GatifloxacinThe serum concentration of Gatifloxacin can be increased when it is combined with Probenecid.Approved, Investigational
GemifloxacinProbenecid may decrease the excretion rate of Gemifloxacin which could result in a higher serum level.Approved, Investigational
GlibornurideThe protein binding of Glibornuride can be decreased when combined with Probenecid.Investigational, Withdrawn
GliclazideThe protein binding of Gliclazide can be decreased when combined with Probenecid.Approved
GlimepirideThe protein binding of Glimepiride can be decreased when combined with Probenecid.Approved
GlipizideThe protein binding of Glipizide can be decreased when combined with Probenecid.Approved
GliquidoneThe protein binding of Gliquidone can be decreased when combined with Probenecid.Approved, Investigational
GlisoxepideThe protein binding of Glisoxepide can be decreased when combined with Probenecid.Approved, Investigational
GlyburideThe protein binding of Glyburide can be decreased when combined with Probenecid.Approved
Glycerol PhenylbutyrateThe serum concentration of the active metabolites of Glycerol Phenylbutyrate can be increased when Glycerol Phenylbutyrate is used in combination with Probenecid.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Probenecid.Investigational, Withdrawn
GuacetisalThe therapeutic efficacy of Probenecid can be decreased when used in combination with Guacetisal.Experimental
Hemoglobin crosfumarilThe therapeutic efficacy of Probenecid can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
HigenamineThe serum concentration of Higenamine can be increased when it is combined with Probenecid.Investigational
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Probenecid.Approved
IbuproxamThe serum concentration of Ibuproxam can be increased when it is combined with Probenecid.Withdrawn
IcatibantThe serum concentration of Icatibant can be increased when it is combined with Probenecid.Approved
Imidazole salicylateThe serum concentration of Imidazole salicylate can be increased when it is combined with Probenecid.Experimental
ImipenemThe serum concentration of Imipenem can be increased when it is combined with Probenecid.Approved
IndobufenThe serum concentration of Indobufen can be increased when it is combined with Probenecid.Investigational
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Probenecid.Approved, Investigational
IndoprofenThe serum concentration of Indoprofen can be increased when it is combined with Probenecid.Withdrawn
IsoxicamThe serum concentration of Isoxicam can be increased when it is combined with Probenecid.Withdrawn
KebuzoneThe serum concentration of Kebuzone can be increased when it is combined with Probenecid.Experimental
KetoprofenThe serum concentration of Ketoprofen can be increased when it is combined with Probenecid.Approved, Vet Approved
KetorolacThe serum concentration of Ketorolac can be increased when it is combined with Probenecid.Approved
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Probenecid.Approved
LeflunomideThe serum concentration of Leflunomide can be increased when it is combined with Probenecid.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Probenecid.Approved, Investigational
LisofyllineThe serum concentration of Lisofylline can be increased when it is combined with Probenecid.Investigational
LonazolacThe serum concentration of Lonazolac can be increased when it is combined with Probenecid.Experimental
LorazepamThe serum concentration of Lorazepam can be increased when it is combined with Probenecid.Approved
LornoxicamThe serum concentration of Lornoxicam can be increased when it is combined with Probenecid.Approved, Investigational
LoxoprofenThe serum concentration of Loxoprofen can be increased when it is combined with Probenecid.Approved, Investigational
LumiracoxibThe serum concentration of Lumiracoxib can be increased when it is combined with Probenecid.Approved, Investigational
Magnesium salicylateThe serum concentration of Magnesium salicylate can be increased when it is combined with Probenecid.Approved
MasoprocolThe serum concentration of Masoprocol can be increased when it is combined with Probenecid.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Probenecid is combined with Mecamylamine.Approved
Meclofenamic acidThe serum concentration of Meclofenamic acid can be increased when it is combined with Probenecid.Approved, Vet Approved
Mefenamic acidThe serum concentration of Mefenamic acid can be increased when it is combined with Probenecid.Approved
MeloxicamThe serum concentration of Meloxicam can be increased when it is combined with Probenecid.Approved, Vet Approved
MeropenemThe serum concentration of Meropenem can be increased when it is combined with Probenecid.Approved, Investigational
MesalazineThe therapeutic efficacy of Probenecid can be decreased when used in combination with Mesalazine.Approved
MetahexamideThe protein binding of Metahexamide can be decreased when combined with Probenecid.Experimental
MetamizoleThe serum concentration of Metamizole can be increased when it is combined with Probenecid.Investigational, Withdrawn
MetampicillinThe serum concentration of Metampicillin can be increased when it is combined with Probenecid.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Probenecid.Approved
Methyl salicylateThe therapeutic efficacy of Probenecid can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MeticillinThe serum concentration of Meticillin can be increased when it is combined with Probenecid.Approved, Investigational
MezlocillinThe serum concentration of Mezlocillin can be increased when it is combined with Probenecid.Approved, Investigational
MinoxidilThe serum concentration of Minoxidil can be increased when it is combined with Probenecid.Approved
MizoribineThe serum concentration of Mizoribine can be increased when it is combined with Probenecid.Investigational
MofebutazoneThe serum concentration of Mofebutazone can be increased when it is combined with Probenecid.Experimental
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Probenecid.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be increased when it is combined with Probenecid.Approved
NabumetoneThe serum concentration of Nabumetone can be increased when it is combined with Probenecid.Approved
NafamostatThe serum concentration of Nafamostat can be increased when it is combined with Probenecid.Approved, Investigational
NafcillinThe serum concentration of Nafcillin can be increased when it is combined with Probenecid.Approved
NaftifineThe serum concentration of Naftifine can be increased when it is combined with Probenecid.Approved
Nalidixic AcidThe serum concentration of Nalidixic Acid can be increased when it is combined with Probenecid.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Probenecid.Approved
NaproxenThe serum concentration of Naproxen can be increased when it is combined with Probenecid.Approved, Vet Approved
NemonoxacinThe serum concentration of Nemonoxacin can be increased when it is combined with Probenecid.Investigational
NepafenacThe serum concentration of Nepafenac can be increased when it is combined with Probenecid.Approved
NifenazoneThe serum concentration of Nifenazone can be increased when it is combined with Probenecid.Experimental
Niflumic AcidThe serum concentration of Niflumic Acid can be increased when it is combined with Probenecid.Approved
NimesulideThe serum concentration of Nimesulide can be increased when it is combined with Probenecid.Approved, Investigational, Withdrawn
NitroaspirinThe therapeutic efficacy of Probenecid can be decreased when used in combination with Nitroaspirin.Investigational
NitrofurantoinThe serum concentration of Nitrofurantoin can be increased when it is combined with Probenecid.Approved, Vet Approved
NorfloxacinThe serum concentration of Norfloxacin can be increased when it is combined with Probenecid.Approved
OlopatadineThe serum concentration of Olopatadine can be increased when it is combined with Probenecid.Approved
OlsalazineThe serum concentration of Olsalazine can be increased when it is combined with Probenecid.Approved
OrgoteinThe serum concentration of Orgotein can be increased when it is combined with Probenecid.Vet Approved
OseltamivirThe serum concentration of the active metabolites of Oseltamivir can be increased when Oseltamivir is used in combination with Probenecid.Approved
OxacillinThe serum concentration of Oxacillin can be increased when it is combined with Probenecid.Approved
OxaprozinThe serum concentration of Oxaprozin can be increased when it is combined with Probenecid.Approved
Oxolinic acidThe serum concentration of Oxolinic acid can be increased when it is combined with Probenecid.Experimental
OxyphenbutazoneThe serum concentration of Oxyphenbutazone can be increased when it is combined with Probenecid.Approved, Withdrawn
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Probenecid.Approved
ParthenolideThe serum concentration of Parthenolide can be increased when it is combined with Probenecid.Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Probenecid.Approved
PazufloxacinThe serum concentration of Pazufloxacin can be increased when it is combined with Probenecid.Investigational
PefloxacinThe serum concentration of Pefloxacin can be increased when it is combined with Probenecid.Approved
PegloticaseThe risk or severity of adverse effects can be increased when Probenecid is combined with Pegloticase.Approved
PenamecillinThe serum concentration of Penamecillin can be increased when it is combined with Probenecid.Experimental
PenimepicyclineThe serum concentration of Penimepicycline can be increased when it is combined with Probenecid.Experimental
PhenoxymethylpenicillinThe serum concentration of Phenoxymethylpenicillin can be increased when it is combined with Probenecid.Approved, Vet Approved
Phenylacetic acidThe serum concentration of Phenylacetic acid can be increased when it is combined with Probenecid.Approved
PhenylbutazoneThe serum concentration of Phenylbutazone can be increased when it is combined with Probenecid.Approved, Vet Approved
Phenylbutyric acidThe serum concentration of the active metabolites of Phenylbutyric acid can be increased when Phenylbutyric acid is used in combination with Probenecid.Approved, Investigational
PimecrolimusThe serum concentration of Pimecrolimus can be increased when it is combined with Probenecid.Approved, Investigational
Pipemidic acidThe serum concentration of Pipemidic acid can be increased when it is combined with Probenecid.Experimental
PiperacillinThe serum concentration of Piperacillin can be increased when it is combined with Probenecid.Approved
PiretanideThe risk or severity of adverse effects can be increased when Probenecid is combined with Piretanide.Experimental
PirfenidoneThe serum concentration of Pirfenidone can be increased when it is combined with Probenecid.Approved, Investigational
Piromidic acidThe serum concentration of Piromidic acid can be increased when it is combined with Probenecid.Experimental
PiroxicamThe serum concentration of Piroxicam can be increased when it is combined with Probenecid.Approved, Investigational
PirprofenThe serum concentration of Pirprofen can be increased when it is combined with Probenecid.Experimental
PivampicillinThe serum concentration of Pivampicillin can be increased when it is combined with Probenecid.Approved
PivmecillinamThe serum concentration of Pivmecillinam can be increased when it is combined with Probenecid.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Probenecid.Approved
PranoprofenThe serum concentration of Pranoprofen can be increased when it is combined with Probenecid.Experimental, Investigational
Procaine benzylpenicillinThe serum concentration of Procaine benzylpenicillin can be increased when it is combined with Probenecid.Approved, Vet Approved
ProglumetacinThe serum concentration of Proglumetacin can be increased when it is combined with Probenecid.Experimental
PropacetamolThe serum concentration of the active metabolites of Propacetamol can be increased when Propacetamol is used in combination with Probenecid.Approved, Investigational
PropicillinThe serum concentration of Propicillin can be increased when it is combined with Probenecid.Experimental
PropyphenazoneThe serum concentration of Propyphenazone can be increased when it is combined with Probenecid.Experimental
ProquazoneThe serum concentration of Proquazone can be increased when it is combined with Probenecid.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Probenecid.Approved
PrulifloxacinThe serum concentration of Prulifloxacin can be increased when it is combined with Probenecid.Investigational
PTC299The serum concentration of PTC299 can be increased when it is combined with Probenecid.Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Probenecid.Approved, Investigational
ResveratrolThe serum concentration of Resveratrol can be increased when it is combined with Probenecid.Approved, Experimental, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Probenecid.Approved, Investigational
RofecoxibThe serum concentration of Rofecoxib can be increased when it is combined with Probenecid.Investigational, Withdrawn
RosoxacinThe serum concentration of Rosoxacin can be increased when it is combined with Probenecid.Approved, Investigational
RufloxacinThe serum concentration of Rufloxacin can be increased when it is combined with Probenecid.Experimental
SalicylamideThe serum concentration of Salicylamide can be increased when it is combined with Probenecid.Approved
Salicylic acidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalsalateThe serum concentration of Salsalate can be increased when it is combined with Probenecid.Approved
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Probenecid.Approved
SemapimodThe serum concentration of Semapimod can be increased when it is combined with Probenecid.Investigational
SeratrodastThe serum concentration of Seratrodast can be increased when it is combined with Probenecid.Approved
SerrapeptaseThe serum concentration of Serrapeptase can be increased when it is combined with Probenecid.Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Probenecid.Approved
SitafloxacinThe serum concentration of Sitafloxacin can be increased when it is combined with Probenecid.Experimental, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Probenecid.Approved, Investigational
SRT501The serum concentration of SRT501 can be increased when it is combined with Probenecid.Investigational
SulbactamThe serum concentration of Sulbactam can be increased when it is combined with Probenecid.Approved
SulbenicillinThe serum concentration of Sulbenicillin can be increased when it is combined with Probenecid.Experimental
SulfasalazineThe serum concentration of Sulfasalazine can be increased when it is combined with Probenecid.Approved
SulindacThe serum concentration of Sulindac can be increased when it is combined with Probenecid.Approved
SultamicillinThe serum concentration of Sultamicillin can be increased when it is combined with Probenecid.Investigational
SuprofenThe serum concentration of Suprofen can be increased when it is combined with Probenecid.Approved, Withdrawn
SuxibuzoneThe serum concentration of Suxibuzone can be increased when it is combined with Probenecid.Experimental
TalampicillinThe serum concentration of Talampicillin can be increased when it is combined with Probenecid.Experimental
TarenflurbilThe serum concentration of Tarenflurbil can be increased when it is combined with Probenecid.Investigational
TazobactamThe serum concentration of Tazobactam can be increased when it is combined with Probenecid.Approved
TemafloxacinThe serum concentration of Temafloxacin can be increased when it is combined with Probenecid.Withdrawn
TenidapThe serum concentration of Tenidap can be increased when it is combined with Probenecid.Experimental
TenoxicamThe serum concentration of Tenoxicam can be increased when it is combined with Probenecid.Approved
TepoxalinThe serum concentration of Tepoxalin can be increased when it is combined with Probenecid.Vet Approved
TeriflunomideThe serum concentration of Teriflunomide can be increased when it is combined with Probenecid.Approved
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Probenecid.Approved
Tiaprofenic acidThe serum concentration of Tiaprofenic acid can be increased when it is combined with Probenecid.Approved
TicarcillinThe serum concentration of Ticarcillin can be increased when it is combined with Probenecid.Approved, Investigational, Vet Approved
TinoridineThe serum concentration of Tinoridine can be increased when it is combined with Probenecid.Investigational
TolazamideThe protein binding of Tolazamide can be decreased when combined with Probenecid.Approved
TolbutamideThe protein binding of Tolbutamide can be decreased when combined with Probenecid.Approved
Tolfenamic AcidThe serum concentration of Tolfenamic Acid can be increased when it is combined with Probenecid.Approved
TolmetinThe serum concentration of Tolmetin can be increased when it is combined with Probenecid.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Probenecid.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Probenecid is combined with Torasemide.Approved
TranilastThe serum concentration of Tranilast can be increased when it is combined with Probenecid.Approved, Investigational
TribenosideThe serum concentration of Tribenoside can be increased when it is combined with Probenecid.Experimental
TriptolideThe serum concentration of Triptolide can be increased when it is combined with Probenecid.Investigational
Trolamine salicylateThe therapeutic efficacy of Probenecid can be decreased when used in combination with Trolamine salicylate.Approved
TrovafloxacinThe serum concentration of Trovafloxacin can be increased when it is combined with Probenecid.Approved, Investigational, Withdrawn
ValdecoxibThe serum concentration of Valdecoxib can be increased when it is combined with Probenecid.Investigational, Withdrawn
ValganciclovirThe serum concentration of Valganciclovir can be increased when it is combined with Probenecid.Approved, Investigational
VincristineThe serum concentration of Vincristine can be increased when it is combined with Probenecid.Approved, Investigational
ZaltoprofenThe serum concentration of Zaltoprofen can be increased when it is combined with Probenecid.Approved, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Probenecid.Approved
ZileutonThe serum concentration of Zileuton can be increased when it is combined with Probenecid.Approved, Investigational, Withdrawn
ZomepiracThe serum concentration of Zomepirac can be increased when it is combined with Probenecid.Withdrawn
Food Interactions
  • Increase liquid intake, avoid alcohol.
  • Take with food to reduce irritation.

References

General References
  1. Butler D: Wartime tactic doubles power of scarce bird-flu drug. Nature. 2005 Nov 3;438(7064):6. [PubMed:16267514]
External Links
Human Metabolome Database
HMDB15166
KEGG Drug
D00475
KEGG Compound
C07372
PubChem Compound
4911
PubChem Substance
46506554
ChemSpider
4742
BindingDB
50206509
ChEBI
8426
ChEMBL
CHEMBL897
Therapeutic Targets Database
DAP001292
PharmGKB
PA451106
IUPHAR
4357
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Probenecid
ATC Codes
M04AB01 — ProbenecidG01AE10 — Combinations of sulfonamides
MSDS
Download (36.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingBasic SciencePre-Exposure Prophylaxis1
0RecruitingTreatmentCalcium Pyrophosphate Deposition Disease1
1CompletedNot AvailableBMI >30 kg/m21
1CompletedBasic ScienceHealthy Volunteers2
1CompletedBasic SciencePharmacokinetics in Healthy Volunteers1
1CompletedHealth Services ResearchAvian Influenza A Virus1
1CompletedOtherHealthy Volunteers1
1CompletedTreatmentBlood And Marrow Transplantation1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1RecruitingOtherHealthy Volunteers1
1RecruitingTreatmentType 2 Diabetes Mellitus1
1WithdrawnTreatmentCytomegalovirus Retinitis / Human Immunodeficiency Virus (HIV) Infections / Infections, Cytomegalovirus1
1, 2CompletedTreatmentPediatric Traumatic Brain Injury1
2CompletedTreatmentBMI >30 kg/m2 / Hyperuricemia / Pre-Hypertension1
2CompletedTreatmentCytomegalovirus Retinitis / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentHeart Failure With Reduced Ejection Fraction (HFrEF)1
4CompletedNot AvailableFlu caused by Influenza1
4CompletedTreatmentCytomegalovirus Retinitis / Human Immunodeficiency Virus (HIV) Infections1
4TerminatedTreatmentEpilepsies1
Not AvailableCompletedBasic ScienceBlood Pressures / BMI >27 kg/m2 / BMI >30 kg/m2 / Endothelial Function / Renal Function1
Not AvailableCompletedTreatmentCytomegalovirus Retinitis / Human Immunodeficiency Virus (HIV) Infections2
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Progressive Multifocal Leukoencephalopathy1
Not AvailableCompletedTreatmentKidney Diseases1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral500 mg
Capsule; tabletOral
TabletOral500 mg/1
Tablet, film coatedOral500 mg/1
TabletOral
Prices
Unit descriptionCostUnit
Probenecid 500 mg tablet1.37USD tablet
Colchicine-Probenecid 0.5-500 mg tablet0.87USD tablet
Benuryl 500 mg Tablet0.21USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)195 °CPhysProp
water solubility27.1 mg/LNot Available
logP3.21HANSCH,C ET AL. (1995)
pKa3.4SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.425 mg/mLALOGPS
logP1.52ALOGPS
logP2.44ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)3.53ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area74.68 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity73.81 m3·mol-1ChemAxon
Polarizability29.96 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9972
Blood Brain Barrier+0.5486
Caco-2 permeable-0.6074
P-glycoprotein substrateNon-substrate0.626
P-glycoprotein inhibitor INon-inhibitor0.8323
P-glycoprotein inhibitor IINon-inhibitor0.9121
Renal organic cation transporterNon-inhibitor0.8253
CYP450 2C9 substrateNon-substrate0.7012
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6485
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8962
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9318
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.6999
BiodegradationNot ready biodegradable0.863
Rat acute toxicity2.2821 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8521
hERG inhibition (predictor II)Non-inhibitor0.7885
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.48 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0f76-0190000000-f6f2df3671a359ea4574
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0f76-0190000000-ce053a8c64308bc3ebbb
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0fen-3950100000-c43ebdb497f6a0e8c974

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzenesulfonamides
Direct Parent
Benzenesulfonamides
Alternative Parents
Benzoic acids / Benzenesulfonyl compounds / Benzoyl derivatives / Organosulfonamides / Aminosulfonyl compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds
show 2 more
Substituents
Benzenesulfonamide / Benzoic acid or derivatives / Benzoic acid / Benzenesulfonyl group / Benzoyl / Organosulfonic acid amide / Organic sulfonic acid or derivatives / Aminosulfonyl compound / Sulfonyl / Organosulfonic acid or derivatives
show 12 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
sulfonamide, benzoic acids (CHEBI:8426)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Takeda M, Narikawa S, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters. Eur J Pharmacol. 2001 May 11;419(2-3):113-20. [PubMed:11426832]
  2. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456]
  3. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
  4. Hashimoto T, Narikawa S, Huang XL, Minematsu T, Usui T, Kamimura H, Endou H: Characterization of the renal tubular transport of zonampanel, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, by human organic anion transporters. Drug Metab Dispos. 2004 Oct;32(10):1096-102. [PubMed:15377641]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Enomoto A, Takeda M, Shimoda M, Narikawa S, Kobayashi Y, Kobayashi Y, Yamamoto T, Sekine T, Cha SH, Niwa T, Endou H: Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther. 2002 Jun;301(3):797-802. [PubMed:12023506]
  2. Babu E, Takeda M, Narikawa S, Kobayashi Y, Enomoto A, Tojo A, Cha SH, Sekine T, Sakthisekaran D, Endou H: Role of human organic anion transporter 4 in the transport of ochratoxin A. Biochim Biophys Acta. 2002 Jun 12;1590(1-3):64-75. [PubMed:12063169]
  3. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
  4. Hashimoto T, Narikawa S, Huang XL, Minematsu T, Usui T, Kamimura H, Endou H: Characterization of the renal tubular transport of zonampanel, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, by human organic anion transporters. Drug Metab Dispos. 2004 Oct;32(10):1096-102. [PubMed:15377641]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140]
  2. Takeda M, Narikawa S, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters. Eur J Pharmacol. 2001 May 11;419(2-3):113-20. [PubMed:11426832]
  3. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456]
  4. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
  5. Sweet DH, Chan LM, Walden R, Yang XP, Miller DS, Pritchard JB: Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to the Na+ gradient. Am J Physiol Renal Physiol. 2003 Apr;284(4):F763-9. Epub 2002 Dec 17. [PubMed:12488248]
  6. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor binding
Specific Function
Structural component of the gap junctions and the hemichannels. May play a role as a Ca(2+)-leak channel to regulate ER Ca(2+) homeostasis.
Gene Name
PANX1
Uniprot ID
Q96RD7
Uniprot Name
Pannexin-1
Molecular Weight
48049.555 Da
References
  1. Silverman W, Locovei S, Dahl G: Probenecid, a gout remedy, inhibits pannexin 1 channels. Am J Physiol Cell Physiol. 2008 Sep;295(3):C761-7. doi: 10.1152/ajpcell.00227.2008. Epub 2008 Jul 2. [PubMed:18596212]
  2. Ransford GA, Fregien N, Qiu F, Dahl G, Conner GE, Salathe M: Pannexin 1 contributes to ATP release in airway epithelia. Am J Respir Cell Mol Biol. 2009 Nov;41(5):525-34. doi: 10.1165/rcmb.2008-0367OC. Epub 2009 Feb 12. [PubMed:19213873]
  3. Ma W, Hui H, Pelegrin P, Surprenant A: Pharmacological characterization of pannexin-1 currents expressed in mammalian cells. J Pharmacol Exp Ther. 2009 Feb;328(2):409-18. doi: 10.1124/jpet.108.146365. Epub 2008 Nov 20. [PubMed:19023039]
  4. Silverman WR, de Rivero Vaccari JP, Locovei S, Qiu F, Carlsson SK, Scemes E, Keane RW, Dahl G: The pannexin 1 channel activates the inflammasome in neurons and astrocytes. J Biol Chem. 2009 Jul 3;284(27):18143-51. doi: 10.1074/jbc.M109.004804. Epub 2009 May 5. [PubMed:19416975]
  5. Bunse S, Locovei S, Schmidt M, Qiu F, Zoidl G, Dahl G, Dermietzel R: The potassium channel subunit Kvbeta3 interacts with pannexin 1 and attenuates its sensitivity to changes in redox potentials. FEBS J. 2009 Nov;276(21):6258-70. doi: 10.1111/j.1742-4658.2009.07334.x. Epub 2009 Sep 24. [PubMed:19780818]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Gustducin-coupled receptor implicated in the perception of bitter compounds in the oral cavity and the gastrointestinal tract. Signals through PLCB2 and the calcium-regulated cation channel TRPM5.
Specific Function
Bitter taste receptor activity
Gene Name
TAS2R16
Uniprot ID
Q9NYV7
Uniprot Name
Taste receptor type 2 member 16
Molecular Weight
33985.52 Da
References
  1. Greene TA, Alarcon S, Thomas A, Berdougo E, Doranz BJ, Breslin PA, Rucker JB: Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin. PLoS One. 2011;6(5):e20123. doi: 10.1371/journal.pone.0020123. Epub 2011 May 24. [PubMed:21629661]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Dundee JW, Halliday NJ, McMurray TJ: Aspirin and probenecid pretreatment influences the potency of thiopentone and the onset of action of midazolam. Eur J Anaesthesiol. 1986 May;3(3):247-51. [PubMed:3780693]
  2. Gewirtz DA, Holt SA: Protein binding as a component of drug interaction in cellular pharmacokinetic studies. Effects of probenecid on transport and accumulation of methotrexate in Ehrlich ascites tumor cells in vitro. Biochem Pharmacol. 1985 Mar 15;34(6):747-54. [PubMed:3977951]
  3. Hansen-Moller J, Schmit U: Rapid high-performance liquid chromatographic assay for the simultaneous determination of probenecid and its glucuronide in urine. Irreversible binding of probenecid to serum albumin. J Pharm Biomed Anal. 1991;9(1):65-73. [PubMed:2043725]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Arndt P, Volk C, Gorboulev V, Budiman T, Popp C, Ulzheimer-Teuber I, Akhoundova A, Koppatz S, Bamberg E, Nagel G, Koepsell H: Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol Renal Physiol. 2001 Sep;281(3):F454-68. [PubMed:11502595]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Arndt P, Volk C, Gorboulev V, Budiman T, Popp C, Ulzheimer-Teuber I, Akhoundova A, Koppatz S, Bamberg E, Nagel G, Koepsell H: Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol Renal Physiol. 2001 Sep;281(3):F454-68. [PubMed:11502595]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocyte...
Gene Name
ABCC3
Uniprot ID
O15438
Uniprot Name
Canalicular multispecific organic anion transporter 2
Molecular Weight
169341.14 Da
References
  1. Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P: Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7. [PubMed:11581266]
  2. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. [PubMed:11585759]
  3. Zamek-Gliszczynski MJ, Xiong H, Patel NJ, Turncliff RZ, Pollack GM, Brouwer KL: Pharmacokinetics of 5 (and 6)-carboxy-2',7'-dichlorofluorescein and its diacetate promoiety in the liver. J Pharmacol Exp Ther. 2003 Feb;304(2):801-9. [PubMed:12538836]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
May be an organic anion pump relevant to cellular detoxification.
Gene Name
ABCC4
Uniprot ID
O15439
Uniprot Name
Multidrug resistance-associated protein 4
Molecular Weight
149525.33 Da
References
  1. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG: The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol. 2002 Mar;13(3):595-603. [PubMed:11856762]
  2. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, Kruh GD: Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50. [PubMed:12036927]
  3. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D: Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology. 2003 Aug;38(2):374-84. [PubMed:12883481]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Acts as a multispecific organic anion pump which can transport nucleotide analogs.
Gene Name
ABCC5
Uniprot ID
O15440
Uniprot Name
Multidrug resistance-associated protein 5
Molecular Weight
160658.8 Da
References
  1. Jedlitschky G, Burchell B, Keppler D: The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem. 2000 Sep 29;275(39):30069-74. [PubMed:10893247]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucin...
Gene Name
SLC16A7
Uniprot ID
O60669
Uniprot Name
Monocarboxylate transporter 2
Molecular Weight
52199.745 Da
References
  1. Broer S, Broer A, Schneider HP, Stegen C, Halestrap AP, Deitmer JW: Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes. Biochem J. 1999 Aug 1;341 ( Pt 3):529-35. [PubMed:10417314]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Isoform 1: May participate directly in the active transport of drugs into subcellular organelles or influence drug distribution indirectly. Transports glutathione conjugates as leukotriene-c4 (LTC4...
Gene Name
ABCC6
Uniprot ID
O95255
Uniprot Name
Multidrug resistance-associated protein 6
Molecular Weight
164904.81 Da
References
  1. Ilias A, Urban Z, Seidl TL, Le Saux O, Sinko E, Boyd CD, Sarkadi B, Varadi A: Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6). J Biol Chem. 2002 May 10;277(19):16860-7. Epub 2002 Mar 5. [PubMed:11880368]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6. [PubMed:11405287]
  2. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol. 2004 Dec;143(7):856-64. Epub 2004 Oct 25. [PubMed:15504753]
  3. Minderman H, Brooks TA, O'Loughlin KL, Ojima I, Bernacki RJ, Baer MR: Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023. Cancer Chemother Pharmacol. 2004 May;53(5):363-9. Epub 2004 Jan 27. [PubMed:15060738]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Hong J, Lambert JD, Lee SH, Sinko PJ, Yang CS: Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res Commun. 2003 Oct 10;310(1):222-7. [PubMed:14511674]
  2. Ilias A, Urban Z, Seidl TL, Le Saux O, Sinko E, Boyd CD, Sarkadi B, Varadi A: Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6). J Biol Chem. 2002 May 10;277(19):16860-7. Epub 2002 Mar 5. [PubMed:11880368]
  3. Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A, Fardel O: Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486. Biochem Biophys Res Commun. 1999 May 19;258(3):513-8. [PubMed:10329417]
  4. Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol. 2000 Apr;57(4):760-8. [PubMed:10727523]
  5. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansen G: Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999 Jun 1;59(11):2532-5. [PubMed:10363967]
  6. Legrand O, Simonin G, Beauchamp-Nicoud A, Zittoun R, Marie JP: Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood. 1999 Aug 1;94(3):1046-56. [PubMed:10419897]
  7. Legrand O, Simonin G, Perrot JY, Zittoun R, Marie JP: Both Pgp and MRP1 activities using calcein-AM contribute to drug resistance in AML. Adv Exp Med Biol. 1999;457:161-75. [PubMed:10500791]
  8. Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, Borst P: Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83. [PubMed:10917554]
  9. Issandou M, Grand-Perret T: Multidrug resistance P-glycoprotein is not involved in cholesterol esterification. Biochem Biophys Res Commun. 2000 Dec 20;279(2):369-77. [PubMed:11118294]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, Sekine T, Endou H, Suzuki H, Sugiyama Y: Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther. 2001 Jul;298(1):316-22. [PubMed:11408557]
  2. Kullak-Ublick GA, Hagenbuch B, Stieger B, Wolkoff AW, Meier PJ: Functional characterization of the basolateral rat liver organic anion transporting polypeptide. Hepatology. 1994 Aug;20(2):411-6. [PubMed:8045503]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucin...
Gene Name
SLC16A1
Uniprot ID
P53985
Uniprot Name
Monocarboxylate transporter 1
Molecular Weight
53943.685 Da
References
  1. Broer S, Broer A, Schneider HP, Stegen C, Halestrap AP, Deitmer JW: Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes. Biochem J. 1999 Aug 1;341 ( Pt 3):529-35. [PubMed:10417314]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Virus receptor activity
Specific Function
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presenc...
Gene Name
SLC10A1
Uniprot ID
Q14973
Uniprot Name
Sodium/bile acid cotransporter
Molecular Weight
38118.64 Da
References
  1. Hagenbuch B, Stieger B, Foguet M, Lubbert H, Meier PJ: Functional expression cloning and characterization of the hepatocyte Na+/bile acid cotransport system. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10629-33. [PubMed:1961729]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Cihlar T, Ho ES: Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1. Anal Biochem. 2000 Jul 15;283(1):49-55. [PubMed:10929807]
  2. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954]
  3. Takeda M, Narikawa S, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters. Eur J Pharmacol. 2001 May 11;419(2-3):113-20. [PubMed:11426832]
  4. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456]
  5. Ichida K, Hosoyamada M, Kimura H, Takeda M, Utsunomiya Y, Hosoya T, Endou H: Urate transport via human PAH transporter hOAT1 and its gene structure. Kidney Int. 2003 Jan;63(1):143-55. [PubMed:12472777]
  6. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
  7. Lu R, Chan BS, Schuster VL: Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am J Physiol. 1999 Feb;276(2 Pt 2):F295-303. [PubMed:9950961]
  8. Race JE, Grassl SM, Williams WJ, Holtzman EJ: Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun. 1999 Feb 16;255(2):508-14. [PubMed:10049739]
  9. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
  10. Kuze K, Graves P, Leahy A, Wilson P, Stuhlmann H, You G: Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells. J Biol Chem. 1999 Jan 15;274(3):1519-24. [PubMed:9880528]
  11. Uwai Y, Saito H, Inui K: Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur J Pharmacol. 2000 Dec 1;409(1):31-6. [PubMed:11099697]
  12. Tsuda M, Sekine T, Takeda M, Cha SH, Kanai Y, Kimura M, Endou H: Transport of ochratoxin A by renal multispecific organic anion transporter 1. J Pharmacol Exp Ther. 1999 Jun;289(3):1301-5. [PubMed:10336520]
  13. Takeda M, Tojo A, Sekine T, Hosoyamada M, Kanai Y, Endou H: Role of organic anion transporter 1 (OAT1) in cephaloridine (CER)-induced nephrotoxicity. Kidney Int. 1999 Dec;56(6):2128-36. [PubMed:10594788]
  14. Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, Sekine T, Endou H, Suzuki H, Sugiyama Y: Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther. 2001 Jul;298(1):316-22. [PubMed:11408557]
  15. Uwai Y, Iwamoto K: Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab Pharmacokinet. 2010;25(2):163-9. [PubMed:20460822]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Not Available
Gene Name
SLC22A10
Uniprot ID
Q63ZE4
Uniprot Name
Solute carrier family 22 member 10
Molecular Weight
60256.57 Da
References
  1. Youngblood GL, Sweet DH: Identification and functional assessment of the novel murine organic anion transporter Oat5 (Slc22a19) expressed in kidney. Am J Physiol Renal Physiol. 2004 Aug;287(2):F236-44. Epub 2004 Apr 6. [PubMed:15068970]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713]
  2. Takeda M, Narikawa S, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters. Eur J Pharmacol. 2001 May 11;419(2-3):113-20. [PubMed:11426832]
  3. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456]
  4. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
  5. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
  6. Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. [PubMed:14762099]
  7. Mori S, Takanaga H, Ohtsuki S, Deguchi T, Kang YS, Hosoya K, Terasaki T: Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J Cereb Blood Flow Metab. 2003 Apr;23(4):432-40. [PubMed:12679720]
  8. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140]
  9. Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, Sekine T, Endou H, Suzuki H, Sugiyama Y: Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther. 2001 Jul;298(1):316-22. [PubMed:11408557]
  10. Nagata Y, Kusuhara H, Endou H, Sugiyama Y: Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol Pharmacol. 2002 May;61(5):982-8. [PubMed:11961115]
  11. Uwai Y, Iwamoto K: Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab Pharmacokinet. 2010;25(2):163-9. [PubMed:20460822]
  12. Lai Y, Sampson KE, Balogh LM, Brayman TG, Cox SR, Adams WJ, Kumar V, Stevens JC: Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1). J Pharmacol Exp Ther. 2010 Sep 1;334(3):936-44. doi: 10.1124/jpet.110.170753. Epub 2010 Jun 2. [PubMed:20519552]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Hong J, Lambert JD, Lee SH, Sinko PJ, Yang CS: Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res Commun. 2003 Oct 10;310(1):222-7. [PubMed:14511674]
  2. Ilias A, Urban Z, Seidl TL, Le Saux O, Sinko E, Boyd CD, Sarkadi B, Varadi A: Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6). J Biol Chem. 2002 May 10;277(19):16860-7. Epub 2002 Mar 5. [PubMed:11880368]
  3. Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol. 2000 Apr;57(4):760-8. [PubMed:10727523]
  4. Horikawa M, Kato Y, Tyson CA, Sugiyama Y: The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab Pharmacokinet. 2002;17(1):23-33. [PubMed:15618649]
  5. Zamek-Gliszczynski MJ, Xiong H, Patel NJ, Turncliff RZ, Pollack GM, Brouwer KL: Pharmacokinetics of 5 (and 6)-carboxy-2',7'-dichlorofluorescein and its diacetate promoiety in the liver. J Pharmacol Exp Ther. 2003 Feb;304(2):801-9. [PubMed:12538836]
  6. Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. doi: 10.1208/s12248-009-9092-5. Epub 2009 Mar 25. [PubMed:19319690]
  7. Chen C, Scott D, Hanson E, Franco J, Berryman E, Volberg M, Liu X: Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats. Pharm Res. 2003 Jan;20(1):31-7. [PubMed:12608533]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Purine nucleotide transmembrane transporter activity
Specific Function
Participates in physiological processes involving bile acids, conjugated steroids and cyclic nucleotides. Enhances the cellular extrusion of cAMP and cGMP. Stimulates the ATP-dependent uptake of a ...
Gene Name
ABCC11
Uniprot ID
Q96J66
Uniprot Name
ATP-binding cassette sub-family C member 11
Molecular Weight
154299.625 Da
References
  1. Chen ZS, Guo Y, Belinsky MG, Kotova E, Kruh GD: Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol Pharmacol. 2005 Feb;67(2):545-57. Epub 2004 Nov 10. [PubMed:15537867]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Enomoto A, Takeda M, Shimoda M, Narikawa S, Kobayashi Y, Kobayashi Y, Yamamoto T, Sekine T, Cha SH, Niwa T, Endou H: Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther. 2002 Jun;301(3):797-802. [PubMed:12023506]
  2. Babu E, Takeda M, Narikawa S, Kobayashi Y, Enomoto A, Tojo A, Cha SH, Sekine T, Sakthisekaran D, Endou H: Role of human organic anion transporter 4 in the transport of ochratoxin A. Biochim Biophys Acta. 2002 Jun 12;1590(1-3):64-75. [PubMed:12063169]
  3. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
  4. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Thyroid hormone transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent high affinity transport of organic anions such as the thyroid hormones thyroxine (T4) and rT3. Other potential substrates, such as triiodothyronine (T3), 17-beta-gluc...
Gene Name
SLCO1C1
Uniprot ID
Q9NYB5
Uniprot Name
Solute carrier organic anion transporter family member 1C1
Molecular Weight
78695.625 Da
References
  1. Tohyama K, Kusuhara H, Sugiyama Y: Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier. Endocrinology. 2004 Sep;145(9):4384-91. Epub 2004 May 27. [PubMed:15166123]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name
SLC22A7
Uniprot ID
Q9Y694
Uniprot Name
Solute carrier family 22 member 7
Molecular Weight
60025.025 Da
References
  1. Enomoto A, Takeda M, Shimoda M, Narikawa S, Kobayashi Y, Kobayashi Y, Yamamoto T, Sekine T, Cha SH, Niwa T, Endou H: Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther. 2002 Jun;301(3):797-802. [PubMed:12023506]
  2. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Urate transmembrane transporter activity
Specific Function
Required for efficient urate re-absorption in the kidney. Regulates blood urate levels. Mediates saturable urate uptake by facilitating the exchange of urate against organic anions.
Gene Name
SLC22A12
Uniprot ID
Q96S37
Uniprot Name
Solute carrier family 22 member 12
Molecular Weight
59629.57 Da
References
  1. Shin HJ, Takeda M, Enomoto A, Fujimura M, Miyazaki H, Anzai N, Endou H: Interactions of urate transporter URAT1 in human kidney with uricosuric drugs. Nephrology (Carlton). 2011 Feb;16(2):156-62. doi: 10.1111/j.1440-1797.2010.01368.x. [PubMed:21272127]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sugar:proton symporter activity
Specific Function
Transport urate and fructose. May have a role in the urate reabsorption by proximal tubules. Also transports glucose at low rate.
Gene Name
SLC2A9
Uniprot ID
Q9NRM0
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 9
Molecular Weight
58701.205 Da
References
  1. Link [Link]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:45